Format

Send to

Choose Destination
Expert Opin Pharmacother. 2008 Oct;9(14):2537-43. doi: 10.1517/14656566.9.14.2537 .

Using risperidone for Alzheimer's dementia-associated psychosis.

Author information

1
Alzheimer's Research and Clinical Programs, VA Medical Center and Medical University of South Carolina, Geriatrics and Extended Care, Charleston, SC, 29406-6076, USA.

Abstract

BACKGROUND:

Alzheimer's dementia (AD) occurs in 6 - 8% of persons older than 65 years. The prevalence increases to 30% among those 85 years or older. Among AD patients, the incidence of psychosis is 30 - 50%. Safe and appropriate use of psychotropic agents is a relevant clinical concern for this population.

OBJECTIVE:

This review addresses risks and potential benefits when risperidone is used for treating AD-associated psychosis.

METHODS:

Through literature review and clinical experience, the authors discuss the clinical efficacy, safety, and regulatory issues concerning risperidone treatment for this group of patients.

CONCLUSION:

Despite concerns about safety, risperidone remains a popular therapeutic choice for AD patients with psychosis. Subsets of these patients with more severe agitation and aggression may experience greater behavioral benefit.

PMID:
18778191
DOI:
10.1517/14656566.9.14.2537
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center